Wednesday, February, 10, 2010
  • Font size
  

Reclast (Zoledronic Acid) Once-a-year Osteoporosis Medicine Approved

Lila de Tantillo
Lila de Tantillo
Close
Journalist, Caregiver

I am a journalist living in Sebring, FL. I have a two-year-old son...

Lila de Tantillo

Sunday, August 19, 2007
View All of Lila de Tantillo's Posts

Zoledronic acid, sold in the U.S. by Novartis under the brand name Reclast, just received final approval from the FDA for the treatment of osteoporosis.

 

The bisphosphonate medication is taken intravenously once a year and has been on the market to treat other bone diseases.

 

Its approval for osteoporosis adds a major new option for those unable to tolerate oral bisphophonate regimens.

 

Check back this week for additional SharePosts on the process of taking Reclast (Zoledronic acid), the potential side effects of the drug, and the long-term outcomes for bone health .  

  • Font size
  • Bookmark
  • Thank you for your input
  • Save
  • RSS
  • Report Abuse

Ask a Question

Get answers from our experts and community members.

View all questions (918) >